Mumbai, Feb. 24 -- These lawsuits were related to allegations of anticompetitive agreements concerning generic Zetia, a cholesterol-lowering drug, and Vytorin, a combination drug.

The lawsuits, consolidated in the Eastern District of Virginia, U.S., alleged that Glenmark entered an anticompetitive settlement in 2010 with Schering Corporation and MSP Singapore Company LLC related to a patent for ezetimibe, the active ingredient in Zetia. Glenmark, along with Merck & Co., Inc., was a defendant in the antitrust and consumer protection litigation.

While Glenmark had previously settled with other plaintiff groups in 2023, these three plaintiffs (Humana, Centene and Kaiser) had opted out. To resolve the ongoing dispute and avoid uncertainty, ...